3 results
Approved WMOPending
Primary Objective:To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.
Approved WMOPending
Primary:- To assess the safety and tolerability of MK2140- To evaluate objective response rate (ORR) of MK2140 as assessed by BICR per RECIST 1.1Secondary:-To evaluate the duration of response (DOR) of MK2140 as assessed by BICR per RECIST 1.1
Approved WMOCompleted
To evaluate the effect of the balance assisting device *GyBAR* on balance capacity during standing and gait tasks in people with pure degenerative ataxia.